Revelation Biosciences (REVB) Non Operating Income (2021 - 2026)
Revelation Biosciences (REVB) posted quarterly Non Operating Income of $60582.0 for Q4 2025, up 115.07% year-over-year from $28169.0 in Q4 2024, and up 69.06% quarter-over-quarter from $35835.0 in Q3 2025.
Revelation Biosciences (REVB) Non Operating Income (2021 - 2026) Analysis & Trends
Revelation Biosciences (REVB) has reported Non Operating Income for 5 consecutive years, with $60582.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income rose 115.07% year-over-year to $60582.0; the TTM figure through Dec 2025 stood at $157166.0 (up 102.23% YoY), while the FY2025 annual figure was $157165.0, up 102.23% from the prior year.
- Non Operating Income advanced to $60582.0 in Q4 2025 per REVB's latest filing, from $35835.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $7.8 million in Q1 2023 and bottomed at -$5.9 million in Q2 2024.
- Historically, Non Operating Income has averaged $81438.0 across 5 years, with a median of $21290.5 in 2022.
- Annual changes were most pronounced in 2023 — Non Operating Income jumped 25823.49% — and 2024, when it tumbled 1310.13%.
- Revelation Biosciences' Non Operating Income stood at -$3439.0 in 2021, then jumped by 412.33% to $10741.0 in 2022, then jumped by 1045.02% to $122987.0 in 2023, then sank by 77.1% to $28169.0 in 2024, then soared by 115.07% to $60582.0 in 2025.
- Business Quant data shows REVB's Non Operating Income at $60582.0 in Q4 2025, $35835.0 in Q3 2025, and $16847.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | 338,857.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 338,857.00 |
| Dec 31, 2025 | 60,582.00 |
| Sep 30, 2025 | 35,835.00 |
| Jun 30, 2025 | 16,847.00 |
| Mar 31, 2025 | 43,902.00 |
| Dec 31, 2024 | 28,169.00 |
| Sep 30, 2024 | -444,879.00 |
| Jun 30, 2024 | -5.87 Mn |
| Mar 31, 2024 | -779,295.00 |
| Dec 31, 2023 | 122,987.00 |
| Sep 30, 2023 | 149,521.00 |
| Jun 30, 2023 | 484,860.00 |
| Mar 31, 2023 | 7.78 Mn |
| Dec 31, 2022 | 10,741.00 |
| Sep 30, 2022 | 28,728.00 |
| Jun 30, 2022 | 25,734.00 |
| Mar 31, 2022 | -30,241.00 |
| Dec 31, 2021 | -3,439.00 |
| Sep 30, 2021 | -557.00 |
| Jun 30, 2021 | -27,714.00 |